Investment opportunity

We are looking for funding in order to move forward with our next clinical trial. Read more below.

Why to invest in Medicortex Finland Oy?

Medicortex is introducing, in Finland, a new diagnostic method for a huge need – detection of brain injury and concussion.

- Large customer potential and variable clients. 

- Current company valuation is ca. 6.5 M€.

- Investor has an exit opportunity if the company is listing on First North at Nasdaq Helsinki (to be considered by the BOD when the valuation is above 10 M€).

- A team of four people keeps the costs low and the organization lean.

- Using professional sub-contractors with qualified track record

Investments will be used for the clinical trial and product development.

- Basic development including preclinical trial and proof-of-concept human testing has been done.

- Patent applications and PCT have been filed.

- Exciting Company, won twice an innovation prize.


Go back to Investors page